Ask any American to describe a prescription drug commercial and you will hear the same thing: a sunlit scene, a hopeful voice, and then a rapid recitation of side effects that seems to last longer than the pitch. That recitation is the law working as intended. Under the Federal Food, Drug, and Cosmetic Act and FDA regulations at 21 C.F.R. § 202.1, an advertisement for a prescription drug must present a "fair balance" of benefits and risks and must not be false or misleading.

Now consider a different commercial. A woman describes bloating, gas, and urgent trips to the bathroom. A narrator suggests these may be symptoms of a condition she has never heard of. A website is offered. No drug is named. No risks are recited, because there is no drug to attach them to. The ad runs for years before the sponsor's product is ever mentioned on television.

That second commercial is a disease awareness campaign, and it is the subject of this article, because the gap it exploits sits at the intersection of two things mass tort lawyers care about: how patients come to take drugs, and what they were told when they did.

The Regulatory Line

FDA's advertising rules attach to promotional labeling and advertising for a specific drug. A communication that discusses a disease and encourages patients to "ask your doctor," without naming or clearly implying a particular product, has generally been treated as a help-seeking or disease awareness communication rather than a drug advertisement. The agency has long maintained that such communications fall outside its advertising regulations, subject to the caveat that an ad which discusses a condition in a way that unmistakably points to one brand may be treated as a branded promotion regardless of whether the name appears.

The commercial logic follows directly. Branded ads must carry the risk disclosure, the "important safety information," and the fair-balance presentation. Unbranded ads carry none of it. If a company can build demand for a diagnosis through unbranded messaging and then capture that demand with a branded product, it has sold the drug without ever having to pair the pitch with the warning.

A Case Study in Building a Market

Exocrine pancreatic insufficiency, or EPI, is a real and sometimes serious condition in which the pancreas fails to produce enough digestive enzymes. It is well documented in patients with cystic fibrosis, chronic pancreatitis, and pancreatic surgery. It was not, until recently, a condition the general public had heard of.

Beginning in the mid-2010s, AbbVie, the manufacturer of the pancreatic enzyme product Creon, funded extensive awareness advertising encouraging people with common gastrointestinal complaints to consider EPI as an explanation. Researchers at Oklahoma State University studied the effect. Their analysis of internet search trends from 2011 to 2021 found statistically significant increases in public interest in EPI after the campaigns began, with search volume peaking in months coinciding with advertising pushes, and noted that AbbVie's advertising spend and Creon's net revenue rose along similar trajectories. The authors framed the result neutrally: increased awareness may support earlier diagnosis of a real condition.

That framing is fair, and it illustrates why this practice resists easy condemnation. Awareness can help underdiagnosed patients. It can also convert transient, self-limiting symptoms into a lifelong pharmaceutical relationship. The literature on this phenomenon, sometimes called disease mongering, has been debated in medical journals for more than two decades. The question for the law is narrower: when the awareness campaign and the product are controlled by the same company, and the product carries risks the campaign never mentions, has the patient been fairly warned?

Why the Regulator Is Paying Attention Now

On September 9, 2025, FDA announced what it called a crackdown on deceptive drug advertising. The agency said it was sending thousands of letters to pharmaceutical companies directing them to remove misleading promotions, issuing approximately 100 cease-and-desist letters, and initiating rulemaking to close the "adequate provision" loophole, a 1997 policy that allowed broadcast ads to summarize only major risks and direct viewers elsewhere for the full picture.

The announcement followed a presidential memorandum directing HHS to increase risk disclosure in direct-to-consumer advertising, and it represented a sharp break from recent enforcement levels. Industry analysts noted that FDA's Office of Prescription Drug Promotion had issued only five untitled letters and no warning letters in all of 2024, compared with 39 untitled and 13 warning letters in 2010. By mid-2026, FDA had issued eight untitled letters through the second quarter and finalized a rule requiring simultaneous audio and text presentation of risk information in broadcast ads.

The next step is now on the calendar. In July 2026, HHS's regulatory agenda listed a proposed FDA rule, "Transparency in Direct-to-Consumer Advertising" (RIN 0910-AJ14), that would amend 21 C.F.R. § 202.1 to eliminate the adequate-provision option and require broadcast ads to carry the necessary risk information themselves. FDA aims to publish the proposal in December 2026, with a final rule targeted for mid-2027. Industry lawyers have described it as a potential de facto ban on broadcast drug ads, and First Amendment challenges are widely expected.

What neither the crackdown nor the proposed rule addresses squarely is the unbranded campaign. The letters and the rulemaking target branded promotion that understates risk. An ad that names no drug remains, formally, outside the frame. In fact, if broadcast branded ads become impractical, unbranded awareness campaigns may become more attractive to marketers, not less. Regulators in other jurisdictions have been more direct; the United Kingdom's medicines regulator has warned for years that awareness campaigns for conditions with only one or a few treatments effectively promote a product whether or not it is named, and require particular care.

The Litigation Angle

Why should a mass tort practitioner care about advertising doctrine? Because the theory of a pharmaceutical failure-to-warn case is that the patient and physician lacked information they needed to make an informed choice. The learned-intermediary doctrine, applied in most states, holds that a manufacturer discharges its duty by warning the prescribing physician, not the patient directly. Direct-to-consumer advertising has always sat uneasily with that doctrine, and a handful of courts have questioned whether a company that markets directly to consumers can rely entirely on the physician as intermediary.

Disease awareness campaigns sharpen the tension. They are, by design, directed at the patient. They shape the conversation the patient will have with the physician. They generate the request that the physician then evaluates. If the campaign is later shown to have expanded the drug's use beyond populations for whom its benefits outweigh its risks, the campaign becomes evidence in three ways: of the company's intent to broaden the market, of its knowledge of the risks it chose not to mention, and of the causal chain from advertisement to prescription to injury.

That is precisely the structure of the government's off-label promotion cases against Eli Lilly (Zyprexa, $1.415 billion, 2009) and Johnson & Johnson (Risperdal, $2.2 billion, 2013), and of the private litigation that followed each. The marketing came first. The injuries came later. The documents connecting them became the case.

Guardrails Worth Considering

Reasonable people disagree about direct-to-consumer drug advertising, which the United States permits and nearly every other developed nation prohibits. But a few principles command broad agreement across that debate:

• An awareness campaign funded by the sole or dominant manufacturer of the treatment should disclose that sponsorship prominently, and the FTC's general sponsorship-disclosure principles already point that direction.
• When a campaign for a condition effectively identifies one product, the risk information that would accompany a branded ad should accompany the campaign.
• Regulators should measure diagnosis and prescribing trends before and after major awareness campaigns, as the Oklahoma State researchers did for EPI, and treat sharp deviations as a signal for review.
• Companies should preserve, and expect to produce, the internal analyses that justified the campaign. In litigation, the strategic memoranda behind an awareness push are often more damaging than the ads themselves.

Conclusion

The law of drug advertising was written for a world in which the pitch and the product arrived together. Marketers separated them. The result is a category of communication that shapes millions of medical decisions while carrying none of the disclosures the law requires of the product it exists to sell. FDA's enforcement turn and its pending rule show the agency is no longer content with the status quo on branded ads. Whether it will reach the unbranded ones is the next question. Until it does, the courtroom remains the place where the gap between what patients were told and what companies knew is measured, one case at a time.

Key Takeaways

• FDA's fair-balance and risk-disclosure rules (21 C.F.R. § 202.1) attach to ads for a specific drug; unbranded "disease awareness" ads that name no product have generally fallen outside them.
• Manufacturers can build demand for a diagnosis through unbranded campaigns and capture it with a branded product, separating the pitch from the warning. Researchers documented this pattern with AbbVie's EPI awareness campaigns and Creon.
• FDA's September 2025 crackdown sent thousands of compliance letters and about 100 cease-and-desist letters, after enforcement had fallen to five untitled letters in 2024.
• A proposed rule to eliminate the "adequate provision" option for broadcast ads (RIN 0910-AJ14) is expected in December 2026, with a final rule targeted for mid-2027. It does not address unbranded awareness ads.
• For failure-to-warn litigation, awareness campaigns are evidence of market-expansion intent, knowledge of undisclosed risks, and the causal chain from ad to prescription, the same structure as the Zyprexa and Risperdal off-label cases.

Frequently Asked Questions

What is a disease awareness advertisement?

An unbranded communication, typically funded by a pharmaceutical company, that describes a medical condition and its symptoms and encourages viewers to consult a physician, without naming a specific drug. Because no drug is named, FDA's risk-disclosure requirements for drug advertising generally do not apply.

Why don't disease awareness ads list side effects?

FDA regulations require fair balance and risk information in advertisements for a specific prescription drug. An ad that does not name or clearly imply a particular product is not a drug advertisement under those rules, so it carries no risk disclosure.

What did FDA announce in September 2025?

On September 9, 2025, FDA and HHS announced a crackdown on misleading direct-to-consumer drug advertising, sending thousands of letters to manufacturers, issuing about 100 cease-and-desist letters, and beginning rulemaking to eliminate the "adequate provision" policy that allowed abbreviated risk disclosures in broadcast ads.

What is FDA's proposed direct-to-consumer advertising rule?

Listed in July 2026 as "Transparency in Direct-to-Consumer Advertising" (RIN 0910-AJ14), it would eliminate the adequate-provision option and require broadcast drug ads to include necessary risk information in the ad itself. FDA aims to publish the proposal in December 2026 and finalize it in mid-2027. Legal challenges are expected.

What is the "adequate provision" loophole?

A 1997 FDA policy allowing broadcast drug ads to present only the major risks while directing viewers to other sources (a website, phone number, print ad, or physician) for complete information. Critics argue it lets ads emphasize benefits while burying risks.

How do awareness campaigns affect drug injury lawsuits?

In failure-to-warn cases, awareness campaigns can serve as evidence that a manufacturer intended to expand a drug's use, knew of risks it did not disclose to consumers, and caused prescriptions that would not otherwise have occurred. They also complicate the learned-intermediary defense by showing direct marketing to patients.

About the Author

Fadi Agour, J.D., is a licensed attorney and the founder and CEO of FadiLaw Marketing LLC, the Houston-based parent company of Best Case Leads, Real Performance Marketing, Masstortsco, and Redostar. For more than seven years he has built performance-marketing companies that connect injured consumers with the plaintiff law firms equipped to represent them. His companies have earned a place on the Inc. 5000 list of America's fastest-growing private companies seven consecutive times (7x Badge). He writes about mass tort litigation, product liability, and the business of plaintiff law.

Sources and Further Reading

1. S. Food and Drug Administration, "FDA Launches Crackdown on Deceptive Drug Advertising" (Sept. 9, 2025): https://www.fda.gov/news-events/press-announcements/fda-launches-crackdown-deceptive-drug-advertising
2. Latham & Watkins, "FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising" (Sept. 2025): https://www.lw.com/en/insights/fda-begins-crackdown-on-direct-to-consumer-pharmaceutical-advertising
3. ProPharma, "FDA Launches Crackdown on Deceptive Drug Advertising" (enforcement statistics, Sept. 10, 2025): https://www.propharmagroup.com/thought-leadership/fda-launches-crackdown-on-deceptive-drug-advertising
4. Mondaq, "FDA Proposes To Eliminate 'Adequate Provision' For Broadcast Prescription Drug Advertising" (July 2026; RIN 0910-AJ14): https://www.mondaq.com/unitedstates/food-and-drugs-law/1814244/fda-proposes-to-eliminate-adequate-provision-for-broadcast-prescription-drug-advertising
5. News/Media Alliance, "FDA Announces Proposed Rule on Direct-to-Consumer Advertising" (July 8, 2026; timeline): https://www.newsmediaalliance.org/fda-announces-proposed-rule-on-direct-to-consumer-advertising/
6. FDA Law Blog (Hyman, Phelps & McNamara), "Coming Soon: Proposed Rule to Remove 'Adequate Provision' (and Ban DTC TV Ads?)" (July 7, 2026): https://www.thefdalawblog.com/2026/07/coming-soon-proposed-rule-to-remove-adequate-provision-and-ban-dtc-tv-ads/
7. Oklahoma State University, "Examining Trends in the Public's Awareness of Exocrine Pancreatic Insufficiency" (Google Trends analysis, 2011–2021): https://scholars.okstate.edu/en/publications/examining-trends-in-the-publics-awareness-of-exocrine-pancreatic-
8. BMJ (via PMC), "Regulator spells out rules on disease awareness campaigns" (MHRA guidance): https://pmc.ncbi.nlm.nih.gov/articles/PMC1126093/
9. Improvado, "Pharma Ad Compliance 2026: FDA & FTC Requirements for Fair Balance and ISI" (21 C.F.R. § 202.1 summary; 2026 enforcement): https://improvado.io/blog/pharma-ad-compliance-fda-ftc-fair-balance-and-isi-requirements
10. S. Department of Justice, Eli Lilly Zyprexa settlement (Jan. 15, 2009): https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa
11. NPR, "Johnson & Johnson To Pay $2.2 Billion In Marketing Settlement" (Nov. 4, 2013): https://www.npr.org/sections/health-shots/2013/11/04/242989557/risperdal-johnson-johnson-to-pay-2-2-billion-in-marketing-settlement
12. 21 C.F.R. § 202.1 (Prescription-drug advertisements).

 

This article is provided for general informational and educational purposes only. It is not legal advice, does not create an attorney-client relationship, and should not be relied upon as a substitute for consultation with a licensed attorney about your specific circumstances. Allegations in pending litigation described here have not been adjudicated, and defendants deny them. Case status, settlement terms, and deadlines change; verify current information with counsel.